Tag:
ruxolitinib
Latest Headlines
Latest Headlines
With promising Ph3 data in hand, Incyte files for myelofibrosis drug OK
Hot on the heels of detailing promising pivotal data on ruxolitinib, Incyte ( $INCY ) filed for FDA approval of the myelofibrosis drug. On Saturday investigators for Incyte and Novartis reported that
Novartis maps out a blockbuster future for INC424
With a solid set of favorable late-stage data from two Phase III trials in its hands, Novartis ( $NVS ) has mapped out a relatively short path to blockbuster status for the experimental cancer drug
Novartis, Incyte ready worldwide apps as cancer drug clears Ph3
An experimental JAK inhibitor under development at Novartis and Incyte hit its primary endpoint in a second late-stage trial, putting the program on track to a second quarter NDA and a possible
